N-(乙酰乙酰基)甘氨酸 | 3103-38-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-(乙酰乙酰基)甘氨酸
• 英文名称: 2-(3-oxobutanamido)acetic acid
• 英文别名: N-acetoacetylglycine；acetoacetylglycine；Acetoacetyl-L-glycin；N-Acetoacetyl-glycin；N-Acetoacetylglycin；Glycine, N-(1,3-dioxobutyl)-；2-(3-oxobutanoylamino)acetic acid
• CAS: 3103-38-6
• 化学式: C₆H₉NO₄
• 分子量: 159.142
• InChiKey: YFMZKFTUZNTQHV-UHFFFAOYSA-N

物化性质

• 熔点：
  93-96 °C
• 沸点：
  443.7±30.0 °C(Predicted)
• 密度：
  1.270±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  83.5
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2924199090

反应信息

• 作为反应物：
  描述：

  N-(乙酰乙酰基)甘氨酸 在 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 sodium hydroxide 作用下， 以 aq. phosphate buffer 、 乙腈 为溶剂， 反应 5.0h， 生成 S-(2-acetamidoethyl) 2-(3-oxobutanamido)ethanethioate
  参考文献：
  名称：

  发现四酸和基于吡啶酮的天然产物生物合成所必需的新的Dieckmann环化酶家族

  摘要：

  生物信息学分析表明，TrdC，SlgL，LipX 2，KirHI和FacHI分别属于一组高度同源的蛋白，这些蛋白与放线菌来源的提拉霉素B，链霉素，α-脂霉素，奇罗霉素和制造霉素的生物合成有关。但是，对其生物合成作用的分配仍然难以捉摸。基因失活和互补，具有合成类似物的体外生化测定，点突变和系统发育树分析表明，这些蛋白质代表了驱动Dimicmann环化酶的新家族，驱动Dimicmann环化酶和吡啶酮支架的生物合成。

  DOI：

  10.1021/ol5036497
• 作为产物：
  描述：

  ethyl-N-(3-oxobutanoyl)glycinate 在 乙醇 、 水 、 sodium hydroxide 作用下， 反应 1.0h， 以78%的产率得到N-(乙酰乙酰基)甘氨酸
  参考文献：
  名称：

  2-Oxoglutarate analogue inhibitors of prolyl hydroxylase domain 2

  摘要：

  Analogues of the 2-oxoglutarate cosubstrate of the human oxygen sensing enzyme prolyl hydroxylase domain 2 (PHD2) with variations in the potential iron-chelating group were screened as inhibitors and for binding (using non-denaturing electrospray ionization mass spectrometry) to PHD2. (c) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.09.005

文献信息

• INTRAVENOUS FORMULATIONS OF COENZYME Q10 (CoQ10) AND METHODS OF USE THEREOF
  申请人：Narain Niven Rajin

  公开号：US20110229554A1

  公开（公告）日：2011-09-22

  Disclosed herein are formulations suitable for parenteral administration of certain hydrophobic active agents such as Coenzyme Q10. Methods of preparing the same and methods of treatment of oncological disorders using the same are also provided herein. The formulations comprise an aqueous solution; a hydrophobic active agent dispersed to form a colloidal nano-dispersion of particles; and at least one of a dispersion stabilizing agent and an opsonization reducer wherein the colloidal nano-dispersion of the active agent is dispersed into nano-dispersion particles having a mean size of less than 200-nm. Methods of preparing the parenteral formulations comprise dispersing the hydrophobic active agent by high pressure homogenization by (1) adding hydrophobic active agent to a 65° C. bath of water and mixing to form a hydrophobic active agent/water mixture; (2) adding a dispersion stabilizing agent to the hydrophobic active agent/water mixture and mix at 65° C. to form a hydrophobic active agent/water/stabilizer mixture; (3) adding an opsonization reducer to form a hydrophobic active agent/water/stabilizer/reducer mixture; (4) pre-heating a Microfluidizer to 65° C.; and (5) processing by mixing the hydrophobic active agent/water/stabilizer/reducer mixture in the Microfluidizer at 65° C. such that a hydrophobic active agent colloidal nano-dispersion having a mean particle size less than 200-nm is formed. Provided herein are also methods of treating oncological disorders by administering formulations described herein to a subject such that treatment or prevention of the oncological disorder occurs.

  本文介绍了适用于亲水性活性剂如辅酶Q10的静脉注射制剂的配方。本文还提供了制备这些制剂的方法以及使用它们治疗肿瘤疾病的方法。该制剂包括水溶液；分散的亲水性活性剂形成的胶体纳米分散液；以及至少一种分散稳定剂和蛋白质封闭还原剂，其中活性剂的胶体纳米分散液分散成平均粒径小于200纳米的纳米分散粒子。制备静脉注射制剂的方法包括通过高压均质法分散亲水性活性剂，包括（1）将亲水性活性剂加入65℃的水中并混合以形成亲水性活性剂/水混合物；（2）向亲水性活性剂/水混合物中加入分散稳定剂并在65℃下混合以形成亲水性活性剂/水/稳定剂混合物；（3）添加蛋白质封闭还原剂以形成亲水性活性剂/水/稳定剂/还原剂混合物；（4）将微流体器加热至65℃；（5）在微流体器中混合亲水性活性剂/水/稳定剂/还原剂混合物以形成平均粒径小于200纳米的亲水性活性剂胶体纳米分散液。本文还提供了将上述配方注射给患者以治疗或预防肿瘤疾病的方法。
• Inhibitors of the advanced glycosylation of proteins and methods of use therefor
  申请人：THE ROCKEFELLER UNIVERSITY

  公开号：EP0450598A2

  公开（公告）日：1991-10-09

  The present invention relates to compositions and methods for inhibiting nonenzymatic cross-linking (protein aging). Accordingly, a composition is disclosed which comprises an agent capable of inhibiting the formation of advanced glycosylation endproducts of target proteins by reacting with a carbonyl moiety of an early glycosylation product of such target proteins resulting from their initial glycosylation. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated. The agents comprise compounds having the following structural formula:         R₁-CH₂-R₂   (I) wherein R₁ is -CN, or R₂ is the same as R₁, or additionally can be -SO₂R, R is a lower alkyl group; R₃ is R, -OH, -OR, -NH₂, -NHNH₂, -NHR; with the proviso that when R₁ and R₂ are independently selected from wherein R₃ is R, -OR or -NHR, then the lower alkyl portion may be an alkanediyl bridge of 1-5 carbon atoms joining the molecule into a cyclic structure; their pharmaceutically acceptable acid addition salts; and    a carrier therefor.

  本发明涉及抑制非酶交联（蛋白质老化）的组合物和方法。因此，本发明公开了一种组合物，该组合物包含一种制剂，能够通过与目标蛋白质因初始糖基化而产生的早期糖基化产物的羰基发生反应，抑制目标蛋白质的晚期糖基化终产物的形成。该方法包括将目标蛋白与组合物接触。本发明既可用于工业，也可用于治疗，因为可以治疗食品腐败和动物蛋白老化。 制剂包括具有以下结构式的化合物： R₁-CH₂-R₂ (I) 其中 R₁ 是-CN，或 R₂ 与 R₁ 相同，或者可以是-SO₂R、 R 是低级烷基； R₃ 是 R、-OH、-OR、-NH₂、-NHNH₂、-NHR； 但当 R₁ 和 R₂ 独立选自以下物质时 其中 R₃ 是 R、-OR 或 -NHR，则低级烷基部分可以是 1-5 个碳原子的烷二基桥，将分子连接成环状结构；它们的药学上可接受的酸加成盐；以及 载体。
• Method of treating or preventing tumors of the central nervous system
  申请人：Berg LLC

  公开号：US10376477B2

  公开（公告）日：2019-08-13

  The invention provides methods and compositions for treatment of a subject with a central nervous system (CNS) tumor comprising administration of Coenzyme Q10 (CoQ10), particularly when the subject exhibits at least one CNS abnormality as a result of the tumor.

  本发明提供了治疗中枢神经系统（CNS）肿瘤患者的方法和组合物，包括服用辅酶Q10（CoQ10），尤其是当患者因肿瘤而表现出至少一种中枢神经系统异常时。
• Topical formulations having enhanced bioavailability
  申请人：Berg LLC

  公开号：US10588859B2

  公开（公告）日：2020-03-17

  The present disclosure provides compositions suitable for delivering lipophilic bioactive agents. The compositions may be utilized to treat numerous diseases and conditions that would benefit from the application of a lipophilic bioactive agent.

  本公开提供了适用于递送亲脂性生物活性剂的组合物。这些组合物可用于治疗多种疾病和病症，这些疾病和病症都会从亲脂性生物活性剂的应用中获益。
• Methods and use of inducing apoptosis in cancer cells
  申请人：Berg LLC

  公开号：US10668028B2

  公开（公告）日：2020-06-02

  The present disclosure relates to a method of inducing apoptosis in a cancer cell by delivery of exogenous Coenzyme Q1O or its metabolites thereof in a pharmaceutically acceptable carrier to effectuate cell contact of endogenous Coenzyme Q1O or its metabolites thereof in addition to but not limited to mevalonic acid and oleic acid to form an intracellular complex. The present disclosure also provides a method of modulating the p53 pathway and Bcl-2 protein family in a manner that restores the apoptotic potential to a cancer cell by delivery of Coenzyme Q1O in a pharmaceutically acceptable carrier. The present disclosure further provides a method to specifically normalize the ratio of pro-apoptotic and anti-apoptotic members of the Bcl-2 gene family in a proportion to re-program a cancer cell to undergo apoptosis.

  本公开涉及一种诱导癌细胞凋亡的方法，通过将外源性辅酶Q1O或其代谢物置于药学上可接受的载体中，使内源性辅酶Q1O或其代谢物与细胞接触，此外还包括但不限于甲羟戊酸和油酸，形成细胞内复合物。本公开还提供了一种通过在药学上可接受的载体中递送辅酶Q1O，以恢复癌细胞凋亡潜能的方式调节p53通路和Bcl-2蛋白家族的方法。本公开进一步提供了一种方法，可特异性地使 Bcl-2 基因家族中促凋亡和抗凋亡成员的比例正常化，从而重新使癌细胞进行凋亡。

表征谱图